Helen Su

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors
    Helen Su
    Department of Molecular Medicine and Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Eur J Nucl Med Mol Imaging 35:1089-99. 2008
  2. pmc Derivation of a compartmental model for quantifying 64Cu-DOTA-RGD kinetics in tumor-bearing mice
    Gregory Z Ferl
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, California 90095 6948, USA
    J Nucl Med 50:250-8. 2009
  3. doi request reprint Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma
    Liu Hua Wei
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Clin Cancer Res 14:3416-26. 2008
  4. pmc Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib
    Rebecca A Dumont
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095 6948, USA
    Cancer Res 69:3173-9. 2009
  5. ncbi request reprint Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors
    Helen Su
    Department of Molecular Medicine and Pharmacology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California at Los Angeles, 650 Charles Young Drive, Los Angeles, CA 90095, USA
    Clin Cancer Res 12:5659-67. 2006
  6. pmc A supramolecular approach for preparation of size-controlled nanoparticles
    Hao Wang
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, 570 Westwood Plaza, Los Angeles, CA 90095, USA
    Angew Chem Int Ed Engl 48:4344-8. 2009
  7. ncbi request reprint Anesthesia and other considerations for in vivo imaging of small animals
    Isabel J Hildebrandt
    Department of Molecular and Medical Pharmacology at the David Geffen School of Medicine at the University of California, Los Angeles, CA 90095 6942, USA
    ILAR J 49:17-26. 2008
  8. ncbi request reprint Monitoring the antitumor response of naive and memory CD8 T cells in RAG1-/- mice by positron-emission tomography
    Helen Su
    Molecular Biology Institute, David Geffen School of Medicine, University of California, Los Angeles, 90095, USA
    J Immunol 176:4459-67. 2006
  9. ncbi request reprint Quantitation of cell number by a positron emission tomography reporter gene strategy
    Helen Su
    Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA
    Mol Imaging Biol 6:139-48. 2004
  10. pmc Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging
    Derek W Bartlett
    Chemical Engineering, California Institute of Technology, 1200 East California Boulevard, MC 210 41, Pasadena, CA 91125, USA
    Proc Natl Acad Sci U S A 104:15549-54. 2007

Detail Information

Publications11

  1. doi request reprint Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors
    Helen Su
    Department of Molecular Medicine and Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Eur J Nucl Med Mol Imaging 35:1089-99. 2008
    ..In this study, we asked whether PET with [(18)F]gefitinib may be used to study noninvasively the pharmacokinetics of gefitinib in vivo and to image the EGFR status of cancer cells...
  2. pmc Derivation of a compartmental model for quantifying 64Cu-DOTA-RGD kinetics in tumor-bearing mice
    Gregory Z Ferl
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, California 90095 6948, USA
    J Nucl Med 50:250-8. 2009
    ..To better understand the PET signal obtained with radiolabeled RGD peptides, we have constructed a compartmental model that can describe the time-activity curves in tumors after an intravenous injection...
  3. doi request reprint Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma
    Liu Hua Wei
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Clin Cancer Res 14:3416-26. 2008
    ..The mechanisms underlying changes in metabolic activity were analyzed by measuring expression and functional activity of enzymes and transporters involved in the uptake of the studied imaging probes...
  4. pmc Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib
    Rebecca A Dumont
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095 6948, USA
    Cancer Res 69:3173-9. 2009
    ..50+/-17.68 mm(2) in controls; P=0.001). [(64)Cu]DOTA-c(RGDfK) may provide a sensitive means of monitoring tumor response to SFK inhibition in alpha(V)beta(3)-expressing cancers early in the course of therapy...
  5. ncbi request reprint Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors
    Helen Su
    Department of Molecular Medicine and Pharmacology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California at Los Angeles, 650 Charles Young Drive, Los Angeles, CA 90095, USA
    Clin Cancer Res 12:5659-67. 2006
    ....
  6. pmc A supramolecular approach for preparation of size-controlled nanoparticles
    Hao Wang
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, 570 Westwood Plaza, Los Angeles, CA 90095, USA
    Angew Chem Int Ed Engl 48:4344-8. 2009
    ..Positron emission tomography (PET) was employed to study the biodistribution and lymph node drainage of the SNPs in mice. The sizes of the SNPs affect their in vivo characteristics (see picture)...
  7. ncbi request reprint Anesthesia and other considerations for in vivo imaging of small animals
    Isabel J Hildebrandt
    Department of Molecular and Medical Pharmacology at the David Geffen School of Medicine at the University of California, Los Angeles, CA 90095 6942, USA
    ILAR J 49:17-26. 2008
    ..Reproducible experimental conditions require clear, consistent reporting, in the study design and throughout the experiment, of the animal strain and gender, fasting, anesthesia, and how often individual animals were imaged...
  8. ncbi request reprint Monitoring the antitumor response of naive and memory CD8 T cells in RAG1-/- mice by positron-emission tomography
    Helen Su
    Molecular Biology Institute, David Geffen School of Medicine, University of California, Los Angeles, 90095, USA
    J Immunol 176:4459-67. 2006
    ..Positron-emission tomography-based immunologic imaging is a noninvasive modality providing unique and meaningful information on the dynamics of the antitumor CTL response...
  9. ncbi request reprint Quantitation of cell number by a positron emission tomography reporter gene strategy
    Helen Su
    Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA
    Mol Imaging Biol 6:139-48. 2004
    ..In this study, we determined the correlation of PET signal to cell number, and characterized the cellular limit of detection for PET imaging...
  10. pmc Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging
    Derek W Bartlett
    Chemical Engineering, California Institute of Technology, 1200 East California Boulevard, MC 210 41, Pasadena, CA 91125, USA
    Proc Natl Acad Sci U S A 104:15549-54. 2007
    ..Optimization of internalization may therefore be key for the development of effective nanoparticle-based targeted therapeutics...
  11. pmc Quantitative imaging of the T cell antitumor response by positron-emission tomography
    Purnima Dubey
    Department of Microbiology and Molecular Genetics, Molecular Biology Institute, University of Padua, I 35128 Padua, Italy
    Proc Natl Acad Sci U S A 100:1232-7. 2003
    ....